Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients: a Pragmatic Trial (EVOLUTION)

NCT05669833 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT05669833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05669833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients: a Pragmatic Trial (EVOLUTION)
Lead sponsor
University of Pennsylvania
Phase
Phase 3
Overall status
Recruiting
Start date
July 14, 2023
Completion date
October 31, 2026
Enrollment
63 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

psoriatic arthritis